Novo Nordisk to Acquire Prothena’s ATTR Amyloidosis Program for ~$1.2B

Shots: Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones Novo Nordisk acquires Prothena’s subsidiary and gets WW rights to the IP and related rights of Prothena’s ATTR amyloidosis business and pipeline. Novo Nordisk will develop the P-II ready Ab PRX004 for ATTR cardiomyopathy …

Novo Nordisk to Acquire Prothena’s ATTR Amyloidosis Program for ~$1.2B Read More »